Mosaic ImmunoEngineering (OTCMKTS:CPMV) and Exicure (NASDAQ:XCUR) Financial Survey

Exicure (NASDAQ:XCUR) and Mosaic ImmunoEngineering (OTCMKTS:CPMV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Valuation and Earnings

This table compares Exicure and Mosaic ImmunoEngineering”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500,000.00	24.21	-$4.95 million	($1.55)	-1.23
Mosaic ImmunoEngineering	N/A	N/A	-$690,000.00	($0.09)	-7.49

Mosaic ImmunoEngineering has lower revenue, but higher earnings than Exicure. Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Exicure and Mosaic ImmunoEngineering, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1	0	0	0	1.00
Mosaic ImmunoEngineering	0	0	0	0	0.00

Profitability

This table compares Exicure and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Mosaic ImmunoEngineering	N/A	N/A	-1,908.81%

Volatility & Risk

Exicure has a beta of 3.61, indicating that its share price is 261% more volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of -0.92, indicating that its share price is 192% less volatile than the S&P 500.

Insider & Institutional Ownership

42.8% of Exicure shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Exicure beats Mosaic ImmunoEngineering on 6 of the 10 factors compared between the two stocks.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.